Search

Search bills, members, committees and pages...

H.R. 2214

U.S. HouseIn House Committee

Summary

H.R. 2214, the DRUG Act, was introduced in the House on Mar 18, 2025 by Rep. Mariannette Miller-Meeks (R) with 6 co-sponsors. It was referred to Energy And Commerce, and last saw action on Mar 18, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


Record

Text

H.R. 2214 has 6 co-sponsors.

hb2214/introduced-in-house.txt
119 HR 2214 IH: Delinking Revenue from Unfair Gouging Act
U.S. House of Representatives
2025-03-18
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
I 119th CONGRESS 1st Session H. R. 2214 IN THE HOUSE OF REPRESENTATIVES March 18, 2025 Mrs. Miller-Meeks (for herself, Ms. Barragán , Ms. Malliotakis , Mr. Schneider , Mr. Allen , and Mr. Norcross ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committees on Ways and Means , and Education and Workforce , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL
To improve services provided by pharmacy benefit managers.
1.
Short title
This Act may be cited as the Delinking Revenue from Unfair Gouging Act or the DRUG Act .
2.
Improving pharmacy benefit manager services
(a)
Public Health Service Act
Part D of title XXVII of the Public Health Service Act ( 42 U.S.C. 300gg–111 et seq. ) is amended by adding at the end the following:
2799A–11.
Improving pharmacy benefit manager services
(a)
In general
Beginning on January 1, 2027, except as provided in subsection (b), a pharmacy benefit manager shall derive no remuneration from any entity for services, benefit administration, or any other activities related to prescription drug benefits under a group health plan or group or individual health insurance coverage.
(b)
Exception for bona fide service fees
(1)
In general
A pharmacy benefit manager may charge an entity a bona fide service fee for the provision of services to such entity only if such fee is set forth in an agreement between the pharmacy benefit manager and such entity and the amount of any bona fide service fee—
(A)
is a flat dollar amount; and
(B)
is not directly or indirectly based on, or contingent upon—
(i)
a drug price (such as wholesale acquisition cost) or drug benchmark price (such as average wholesale price);
(ii)
the amount of discounts, rebates, fees, or other direct or indirect remuneration with respect to prescription drugs prescribed to the participants, beneficiaries, or enrollees in the group health plan or health insurance coverage involved; or
(iii)
any other amounts specified by the Secretary, the Secretary of Labor, and the Secretary of the Treasury;
(2)
Definitions
In this section—
(A)
the term bona fide service fee means a fee that is equal to the fair market value of a bona fide, itemized service that is actually performed on behalf of an entity, that the entity would otherwise perform (or contract for) in the absence of the service arrangement, and that is not passed on in whole or in part to a client or customer, whether or not the entity takes title to the drug; and
(B)
the term pharmacy benefit manager means any person, business, or other entity, such as a third-party administrator, regardless of whether it identifies itself as a pharmacy benefit manager, that, either directly or through an intermediary (including an affiliate, subsidiary, or agent) or an arrangement with a third-party—
(i)
acts a price negotiator for prescription drugs on behalf of a group health plan or health insurance issuer offering group or individual health insurance coverage; or
(ii)
manages or administers the prescription drug benefits provided by a group health plan or health insurance issuer offering group or individual health insurance coverage, including creating formularies, the processing and payment of claims for prescription drugs, arranging alternative access to or funding for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with network pharmacies (including retail and mail pharmacies), controlling the cost of covered prescription drugs, or the provision of related services.
(c)
Enforcement
(1)
In general
The Secretary, in consultation with the Secretary of Labor and the Secretary of the Treasury, shall enforce this section.
(2)
Disgorgement
The pharmacy benefit manager shall disgorge to a group health plan or health insurance issuer offering group or individual health insurance coverage any payment, remuneration, or other amount received by the pharmacy benefit manager or an affiliate of such pharmacy benefit manager from such plan or issuer in violation of subsection (a) or, pursuant to subsection (b), the agreement entered into with such plan or issuer for bona fide service fees.
(3)
Penalties
A pharmacy benefit manager that violates subsection (a) or (b) shall be subject to a civil monetary penalty in the amount of $10,000 for each day during which such violation continues.
(4)
Procedure
Notwithstanding section 2723, the provisions of section 1128A of the Social Security Act, other than subsection (a) and (b) and the first sentence of subsection (c)(1) of such section, shall apply to civil monetary penalties under this subsection in the same manner as such provisions apply to a penalty or proceeding under section 1128A of the Social Security Act.
(d)
Regulations
Notwithstanding any other provision of law, the Secretary, in consultation with the Secretary of Labor and the Secretary of the Treasury, shall implement this section through interim final regulations.
(e)
Rules of construction
Nothing in this section shall be construed—
(1)
as prohibiting payments related to reimbursement for ingredient costs to entities that acquire prescription drugs or pharmacy dispensing fees; and
(2)
to prohibit rebates, discounts, or other price concessions from being fully passed through to a group health plan or health insurance issuer offering group or individual health insurance coverage to lower net costs for prescription drugs.
.
(b)
ERISA
(1)
In general
Subpart B of part 7 of subtitle B of title I of the Employee Retirement Income Security Act of 1974 ( 29 U.S.C. 1185 et seq. ) is amended by inserting after section 725 the following:
726.
Improving pharmacy benefit manager services
(a)
General
Beginning on January 1, 2027, except as provided in subsection (b), a pharmacy benefit manager shall derive no remuneration from any entity for services, benefit administration, or any other activities related to prescription drug benefits under a group health plan or group health insurance coverage.
(b)
Exception for bona fide service fees
(1)
In general
A pharmacy benefit manager may charge an entity a bona fide service fee for the provision of services to an entity only if such fee is set forth in an agreement between the pharmacy benefit manager and such entity and the amount of any bona fide service fee—
(A)
is a flat dollar amount; and
(B)
is not directly or indirectly based on, or contingent upon—
(i)
a drug price (such as wholesale acquisition cost) or drug benchmark price (such as average wholesale price);
(ii)
the amount of discounts, rebates, fees, or other direct or indirect remuneration with respect to prescription drugs prescribed to the participants, beneficiaries, or enrollees in the group health plan or health insurance coverage involved; or
(iii)
any other amounts specified by the Secretary, the Secretary of Health and Human Services, and the Secretary of the Treasury.
(2)
Definitions
In this section—
(A)
the term bona fide service fee means a fee that is equal to the fair market value of a bona fide, itemized service that is actually performed on behalf of an entity, that the entity would otherwise perform (or contract for) in the absence of the service arrangement, and that is not passed on in whole or in part to a client or customer, whether or not the entity takes title to the drug; and
(B)
the term pharmacy benefit manager means any person, business, or other entity, such as a third-party administrator, regardless of whether it identifies itself as a pharmacy benefit manager, that, either directly or through an intermediary (including an affiliate, subsidiary, or agent) or an arrangement with a third-party—
(i)
acts a price negotiator for prescription drugs on behalf of a group health plan or health insurance issuer offering group health insurance coverage; or
(ii)
manages or administers the prescription drug benefits provided by a group health plan or health insurance issuer offering group health insurance coverage, including creating formularies, the processing and payment of claims for prescription drugs, arranging alternative access to or funding for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with network pharmacies (including retail and mail pharmacies), controlling the cost of covered prescription drugs, or the provision of related services.
(c)
Enforcement
The Secretary shall enforce this section as provided for in section 502(c)(13).
(d)
Regulations
Notwithstanding any other provision of law, the Secretary, in consultation with the Secretary of Health and Human Services and the Secretary of the Treasury, shall implement this section through interim final regulations.
(e)
Rules of construction
Nothing in this section shall be construed—
(1)
as prohibiting payments related to reimbursement for ingredient costs to entities that acquire prescription drugs or pharmacy dispensing fees; and
(2)
to prohibit rebates, discounts, or other price concessions from being fully passed through to a group health plan or health insurance issuer offering group health insurance coverage to lower net costs for prescription drugs.
.
(2)
Enforcement
Section 502 of the Employee Retirement Income Security Act of 1974 ( 29 U.S.C. 1132 ) is amended—
(A)
in subsection (a)(6), by striking or (9) and inserting (9), or (13) ; and
(B)
in subsection (c), by adding at the end the following:
(13)
Secretarial enforcement authority relating to pharmacy benefit manager services
(A)
Disgorgement
With respect to a violation of section 726 by a pharmacy benefit manager, such pharmacy benefit manager shall disgorge to a group health plan or health insurance issuer offering group health insurance coverage any payment, remuneration, or other amount received by the pharmacy benefit manager or an affiliate of such pharmacy benefit manager from such plan or issuer in violation of subsection (a) of such section or, pursuant to subsection (b) of such section, the agreement entered into with such plan or issuer for bona fide service fees.
(B)
Penalties
A pharmacy benefit manager that violates subsection (a) or (b) of section 726 shall be subject to a civil monetary penalty in the amount of $10,000 for each day during which such violation continues.
(C)
Procedure
Except as provided in this paragraph, the provisions of this section shall apply to civil monetary penalties under this paragraph in the same manner as such provisions apply to other civil penalties under this section.
(D)
Rule of construction
Nothing in this paragraph shall effect the authority of the Secretary under subsection (a)(5).
.
(3)
Clerical amendment
The table of contents in section 1 of the Employee Retirement Income Security Act of 1974 ( 29 U.S.C. 1001 et seq. ) is amended by inserting after the item relating to section 725 the following new item:
Sec. 726. Improving pharmacy benefit manager services.
(c)
Internal Revenue Code of 1986
(1)
In general
Subchapter B of chapter 100 of the Internal Revenue Code of 1986 is amended by adding at the end the following:
9826.
Improving pharmacy benefit manager services
(a)
In general
Beginning on January 1, 2027, except as provided in subsection (b), a pharmacy benefit manager shall derive no remuneration from any entity for services, benefit administration, or any other activities related to prescription drug benefits under a group health plan.
(b)
Exception for bona fide service fees
(1)
In general
A pharmacy benefit manager may charge an entity a bona fide service fee for the provision of services to such entity only if such fee is set forth in an agreement between the pharmacy benefit manager and such entity and the amount of any bona fide service fee—
(A)
is a flat dollar amount; and
(B)
is not directly or indirectly based on, or contingent upon—
(i)
a drug price (such as wholesale acquisition cost) or drug benchmark price (such as average wholesale price);
(ii)
the amount of discounts, rebates, fees, or other direct or indirect remuneration with respect to prescription drugs prescribed to the participants, beneficiaries, or enrollees in the group health plan involved; or
(iii)
any other amounts specified by the Secretary, the Secretary of Health and Human Services, and the Secretary of the Labor.
(2)
Definitions
In this section—
(A)
the term bona fide service fee means a fee that is equal to the fair market value of a bona fide, itemized service that is actually performed on behalf of an entity, that the entity would otherwise perform (or contract for) in the absence of the service arrangement, and that is not passed on in whole or in part to a client or customer, whether or not the entity takes title to the drug; and
(B)
the term pharmacy benefit manager means any person, business, or other entity such as a third-party administrator, regardless of whether it identifies itself as a pharmacy benefit manager, that, either directly or through an intermediary (including an affiliate, subsidiary, or agent) or an arrangement with a third-party—
(i)
acts as a price negotiator for prescription drugs on behalf of a group health plan; or
(ii)
manages or administers the prescription drug benefits provided by a group health plan, including creating formularies, the processing and payment of claims for prescription drugs, arranging alternative access to or funding for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with network pharmacies, controlling the cost of covered prescription drugs, or the provision of related services.
(c)
Enforcement
(1)
In general
The Secretary, in consultation with the Secretary of Health and Human Services and the Secretary of Labor, shall enforce this section.
(2)
Disgorgement
The pharmacy benefit manager shall disgorge to a group health plan any payment, remuneration, or other amount received by the pharmacy benefit manager or an affiliate of such pharmacy benefit manager from such plan or issuer in violation of subsection (a) or, pursuant to subsection (b), the agreement entered into with such plan for bona fide service fees.
(3)
Penalties
A pharmacy benefit manager that violates subsection (a) or (b) shall be subject to a civil monetary penalty in the amount of $10,000 for each day during which such violation continues.
(4)
Procedure
The provisions of section 1128A of the Social Security Act, other than subsection (a) and (b) and the first sentence of subsection (c)(1) of such section, shall apply to civil monetary penalties under this subsection in the same manner as such provisions apply to a penalty or proceeding under section 1128A of the Social Security Act.
(d)
Regulations
Notwithstanding any other provision of law, the Secretary, in consultation with the Secretary of Health and Human Services and the Secretary of Labor, shall implement this section through interim final regulations.
.
(2)
Clerical amendment
The table of sections for subchapter B of chapter 100 of the Internal Revenue Code of 1986 is amended by adding at the end the following new item:
Sec. 9826. Improving pharmacy benefit manager services.
.

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2025-03-18
  2. Passed House
  3. Passed Senate
  4. Conference
  5. To President
  6. Became Law

To improve services provided by pharmacy benefit managers.

Sponsors

Rep. Mariannette Miller-Meeks (R) sponsors H.R. 2214, and 6 members have co-sponsored it, 5 of them from the day it was introduced.

Committees

H.R. 2214 went before 3 committees: Education and Workforce, Ways and Means and Energy and Commerce.

Education and Workforce
Education and Workforce
Referred To · Mar 18, 2025 · 824 Bills
Ways and Means
Ways and Means
Referred To · Mar 18, 2025 · 1,160 Bills
Energy and Commerce
Energy and Commerce
Referred To · Mar 18, 2025 · 1,636 Bills

Actions

H.R. 2214 has taken 2 actions since Mar 18, 2025.

ChamberAction
Mar 18, 2025
House
Introduced in House
Mar 18, 2025
House
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.Energy and Commerce Committee

Votes

H.R. 2214 has not gone to a roll call.

Titles

H.R. 2214 goes by 4 titles, 2 of them short titles.

  • DRUG Act — Display Title
  • DRUG Act — Short Title(s) as Introduced
  • Delinking Revenue from Unfair Gouging Act — Short Title(s) as Introduced
  • To improve services provided by pharmacy benefit managers. — Official Title as Introduced

Lobbying

22 clients hired 28 firms and 182 registered lobbyists who named H.R. 2214 in 142 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Health Issues, Medicare/Medicaid, Pharmacy, Trade (domestic/foreign), Budget/Appropriations, Copyright/Patent/Trademark, Taxation/Internal Revenue Code, Defense.

Clients

Who paid to be heard, by how many filings named the bill. The 20 that filed most often, of 22.

ClientBusinessStateFirmsFilingsReported
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATIONtrade association representing Americas pharmacy benefits managersDistrict of Columbia317$560K
PRIME THERAPEUTICSPharmacy Benefit ManagementMinnesota312$200K
PFIZER INC.Biopharmaceutical company.District of Columbia211$260K
NOVARTISDistrict of Columbia18
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)Trade association for the Pharmaceutical Research and Manufacturer's of AmericaDistrict of Columbia17$280K
ELEVANCE HEALTH, INC.District of Columbia17
GSK (FKA GLAXOSMITHKLINE INC.)District of Columbia17
THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)District of Columbia17
SOUTHEAST GEORGIA HOSPITAL SYSTEMHospital System, three hospitals and a nursing homeGeorgia16$120K
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)District of Columbia16
CVS HEALTH (AND SUBSIDIARIES)Health CareDistrict of Columbia16
EMD SERONO INCDistrict of Columbia16
JOHNSON & JOHNSON SERVICES INCNew Jersey16
NATIONAL COMMUNITY PHARMACISTS ASSOCIATIONVirginia16
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICADistrict of Columbia16
YC CONSULTING, LLC ON BEHALF OF PATIENTS RISING NOWGovernment affairs and strategic advisory services firmDistrict of Columbia25$30K
AMGEN INCDistrict of Columbia15
GOVERNMENT COUNSEL, LLC (OBO) PRIME THERAPEUTICS​Public Policy and Government Advisory FirmFlorida14$40K
AMERICAN PHARMACIES, INC.Independent pharmacy services groupTexas13$180K
TAKEDA PHARMACEUTICALS AMERICA INCDistrict of Columbia13

Firms

Registrants who filed on the bill, by filings.

Lobbyists

Named on the filings that cite the bill. The 20 named most often, of 182.

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

ClientRegistrantPeriodReportedDocument
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2025 first_quarter$12.9M1st Quarter - Report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2026 first_quarter$12.2M1st Quarter - Report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2025 third_quarter$9M3rd Quarter - Report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2025 fourth_quarter$8.4M4th Quarter - Report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2025 second_quarter$7.6M2nd Quarter - Report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2026 second_quarter$7.4M2nd Quarter - Report
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)2026 first_quarter$5.3M1st Quarter - Report
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)2025 first_quarter$4.8M1st Quarter - Report
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)2025 third_quarter$4.2M3rd Quarter - Report
NOVARTISNOVARTIS2025 first_quarter$4.2M1st Quarter - Report
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)2025 fourth_quarter$4.1M4th Quarter - Report
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATIONPHARMACEUTICAL CARE MANAGEMENT ASSOCIATION2025 first_quarter$4.1M1st Quarter - Report
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)2025 second_quarter$4.1M2nd Quarter - Report
NOVARTISNOVARTIS2026 first_quarter$3.9M1st Quarter - Report
PFIZER INC.PFIZER INC.2025 second_quarter$3.7M2nd Quarter - Amendme…
PFIZER INC.PFIZER INC.2025 second_quarter$3.7M2nd Quarter - Amendme…
AMGEN INCAMGEN, INC.2025 first_quarter$3.6M1st Quarter - Report
CVS HEALTH (AND SUBSIDIARIES)CVS HEALTH (AND SUBSIDIARIES)2026 second_quarter$3.6M2nd Quarter - Report
AMGEN INCAMGEN, INC.2025 fourth_quarter$3.6M4th Quarter - Report
AMGEN INCAMGEN, INC.2025 third_quarter$3.6M3rd Quarter - Report

Classification

The Congressional Research Service files H.R. 2214 under Health, one of its 31 policy areas.

CRS Subjects

CRS assigns every bill one policy area from its 31; H.R. 2214’s is Health.

hr2214/policy-areas.txt
HealthAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTaxationTransportation and Public WorksWater Resources Development

Source: congress.gov · legiscan.com